We are pleased to share our article Metabolic Dysfunction and Alcohol-related Liver Disease (MetALD): Position statement by an expert panel on alcohol-related liver disease. Now available online in @jhepatology.bsky.social @MATHURINPHILIP1 #LiverSky #LiverSky authors.elsevier.com/a/1kOr5cOnAU...

Since we are in the Christmas spirit, Merry Christmas to all the researchers out there! #LiverSky

Seeing high MELD patients w/ ALD who re-compensate with sobriety & get their lives back (and avoid transplant!) is incredibly rewarding. As Hepatologists treating ALD, it is essential that we treat the underlying alcohol use disorder so our patients can improve! @juanpabloarab.bsky.social #liversky

There are *some* people whom steroids help There is still value in trials, pragmatic trials, that refine inclusion criteria, dose, duration, and stopping rules @anandvkulkarni.bsky.social @juanpabloarab.bsky.social @blaneymd.bsky.social

Don’t miss this December ENTIRE issue of HEPATOLOGY Journal dedicated to #ALD Presented here by Dr. Michael R. Lucey @uwsmph @AASLDtweets Watch: buff.ly/41JYkRG

🚨 ‼️Very Important Paper: @HarishGMD et al. 📢 Drug induced liver injury from medications for alcohol use disorder Key insights from US DILI Network @livertox @NIDDKgov @nagachalasani pubmed.ncbi.nlm.nih.gov/39651750/

ALD and MASLD are a lot alike. How do we tell them apart on pathology? Cindy Behling walks us through in this fantastic talk. 👏 #TLM24 #Liversky @juanpabloarab.bsky.social #pathologysky

Happy to share our findings about naltrexone in decompensated cirrhosis, at #TLM2024. Grateful for the support of my mentors Dr Devuni, @juanpabloarab.bsky.social, and my excellent co-author Dr Cooper! #LiverSky

Congrats to inspiring investigators @anandvkulkarni.bsky.social @juanpabloarab.bsky.social and team, for late breaking abstract about rapid taper of steroids in AAH at #TLM24 ⤵️ infections, hospitalizations with rapid taper 💫 changing practice in management of AAH #LiverSky #AASLD